FDA Dismisses List Of “Grandfathered” Ingredients In Pyridoxamine Decision
This article was originally published in The Tan Sheet
Executive Summary
Companies determining whether a substance is a new dietary ingredient cannot rely on industry-developed lists of "grandfathered" ingredients believed to be marketed prior to the Dietary Supplement Health and Education Act, FDA says in response to a citizen petition
You may also be interested in...
Pyridoxamine Petition Paints Better Option As Dietary Ingredient Than IND
ViGuard Health says in a petition that with two IND programs for studies of pyridoxamine's potential therapeutic use formally withdrawn, FDA should rescind its 2009 decision that it did not qualify as a dietary ingredient.
Amarin's Omega-3 Fair Trade Complaint Reaches Regulatory Dead End
International Trade Commission won't investigate Amarin's complaint that some dietary supplements containing omega-3 formulations similar to icosapent ethyl in its Vascepa are actually drugs and should be blocked from import into US, likely discouraging others from this novel approach.
Pyridoxamine Debate Continues; CRN Points To Ingredient’s Presence In Food
Pyridoxamine's presence in many common foods makes it exempt from 75-day premarket notification, the Council for Responsible Nutrition maintains in comments supporting the ingredient's status as a dietary supplement